Nasal Polyposis Market Size in the 7MM was USD 1,531.9 million in 2021, which is further expected to increase by 2034. Several key companies are active in the therapeutics market.

Nasal Polyposis Market Size, Share, Market Trends, Key Companies

Nasal Polyposis Market

1 Key Insights
 
2 Report Introduction
 
3 Nasal Polyposis (NP) Market Overview at a Glance
 
3.1. Market Share (%) Distribution of Nasal Polyposis (NP) by Therapies in 2020
 
3.2. Market Share (%) Distribution of Nasal Polyposis (NP) by Therapies in 2034
 
4 Nasal Polyposis Market: Future Perspective
 
5 Executive Summary of Nasal Polyposis
 
6 Key Events
 
7 Disease Background and Overview: Nasal Polyposis
 
7.1. Introduction
 
7.2. Signs and Symptoms
 
7.3. Etiology
 
7.4. Causes
 
7.5. Pathogenesis
 
7.6. Diagnostic Approach
 
7.6.1. JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis
 
7.6.2. Diagnostic Algorithm
 
7.7. Treatment and Management
 
7.7.1. Treatment Algorithm
 
7.7.2. Treatment Recommendations
 
7.7.2.1. European forum for research and education in allergy and airway diseases
 
7.7.2.2. International Consensus Statement on Rhinology and Allergy
 
8 Epidemiology and Patient Population
 
8.1. Key Findings
 
8.2. Methodology of Epidemiology
 
8.3. Assumptions and Rationale: 7MM
 
8.3.1. United States
 
8.3.2. EU4 and the UK (Germany, France, Italy, Spain and the United Kingdom)
 
8.3.3. Japan
 
8.4. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM
 
8.5. Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM
 
8.6. The United States
 
8.6.1. Prevalent Cases of Chronic Rhinosinusitis in the United States
 
8.6.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the United States
 
8.6.3. Diagnosed Prevalent Cases of Nasal Polyposis in the United States
 
8.6.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the United States
 
8.7. EU4 and the UK
 
8.7.1. Prevalent Cases of Chronic Rhinosinusitis in the EU4 and the UK
 
8.7.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU4 and the UK
 
8.7.3. Diagnosed Prevalent Cases of Nasal Polyposis in the EU4 and the UK 
 
8.7.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU4 and the UK
 
8.8. Japan
 
8.8.1. Prevalent Cases of Chronic Rhinosinusitis in Japan
 
8.8.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan
 
8.8.3. Diagnosed Prevalent Cases of Nasal Polyposis in Japan
 
8.8.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan
 
9 Patient Journey
 
10 Marketed Therapies
 
10.1. Nucala (Mepolizumab): GlaxoSmithKline
 
10.1.1. Product Description
 
10.1.2. Regulatory Milestones
 
10.1.3. Other Developmental activities
 
10.1.4. Clinical Development
 
10.1.5. Clinical Trials Information
 
10.1.6. Safety and Efficacy
 
10.1.7. Product Profile
 
10.1.8. Analysts&rsquo; Views
 
10.2. Xhance (Fluticasone Propionate): Optinose US Inc.
 
10.2.1. Product Description
 
10.2.2. Regulatory Milestones
 
10.2.3. Other Developmental activities
 
10.2.4. Clinical Development
 
10.2.5. Clinical Trials Information
 
10.2.6. Safety and Efficacy
 
10.2.7. Product Profile
 
10.3. Dupixent (Dupilumab): Sanofi/Regeneron Pharmaceuticals
 
10.3.1. Product Description
 
10.3.2. Regulatory Milestones
 
10.3.3. Other Developmental activities
 
10.3.4. Clinical Development
 
10.3.5. Clinical Trials Information
 
10.3.6. Safety and Efficacy
 
10.3.7. Product Profile
 
10.3.8. Analysts&rsquo; Views
 
10.4. Xolair (Omalizumab): Hoffmann-La Roche/Novartis
 
10.4.1. Product Description
 
10.4.2. Regulatory Milestones
 
10.4.3. Other Developmental activities
 
10.4.4. Clinical Development
 
10.4.5. Clinical Trials Information
 
10.4.6. Safety and Efficacy
 
10.4.7. Product Profile
 
10.4.8. Analysts&rsquo; Views
 
10.5. Sinuva (Mometasone Furoate) Sinus Implant: Intersect ENT
 
10.5.1. Product Description
 
10.5.2. Regulatory Milestones
 
10.5.3. Clinical Development
 
10.5.4. Clinical Trials Information
 
10.5.5. Safety and Efficacy
 
10.5.6. Product Profile
 
10.6. Propel (Mometasone Furoate): Intersect ENT
 
10.6.1. Product Description
 
10.6.2. Regulatory Milestones
 
10.6.3. Other Developmental activities
 
10.6.4. Clinical Development
 
10.6.5. Clinical Trials Information
 
10.6.6. Safety and Efficacy
 
10.6.7. Product Profile
 
11 Emerging Drugs
 
11.1. Key Cross Competition
 
11.2. Fasenra (benralizumab): AstraZeneca
 
11.2.1. Product Description
 
11.2.2. Development activities
 
11.2.3. Clinical Development
 
11.2.4. Clinical Trials Information
 
11.2.5. Safety and Efficacy
 
11.2.6. Product Profile
 
11.2.7. Analysts&rsquo; Views
 
11.3. Tezepelumab: AstraZeneca/Amgen
 
11.3.1. Product Description
 
11.3.2. Development activities
 
11.3.3. Clinical Development
 
11.3.4. Clinical Trials Information
 
11.3.5. Safety and Efficacy
 
11.3.6. Product Profile
 
11.3.7. Analysts&rsquo; Views
 
List to be continued in the report&hellip;..
 
12 Nasal Polyposis (NP): Seven Major Market Analysis
 
12.1. Key Findings
 
12.2. Methodology of Nasal Polyposis (NP) Market
 
12.3. Market Size of Nasal Polyposis in the 7MM
 
12.4. Market Size of Nasal Polyposis by Therapies in the 7MM
 
12.5. Potential of Emerging Biologics in the Nasal Polyposis Treatment Market
 
12.6. Key Market Forecast Assumptions
 
12.7. Conjoint Analysis
 
12.8. Market Outlook
 
12.9. Market Size of Nasal Polyposis in the United States
 
12.9.1. Total Market Size of Nasal Polyposis
 
12.9.2. Market Size of Nasal Polyposis by Therapies
 
12.10. Market Size of Nasal Polyposis in the EU4 and the UK
 
12.10.1. Total Market Size of Nasal Polyposis
 
12.10.2. Market Size of Nasal Polyposis by Therapies
 
12.11. Market Size of Nasal Polyposis in Japan
 
12.11.1. Total Market Size of Nasal Polyposis
 
12.11.2. Market Size of Nasal Polyposis by Therapies
 
13 KOL Views
 
13.1. United States
 
13.2. EU4 and the UK
 
13.3. Japan
 
14 SWOT Analysis
 
15 Unmet Needs
 
16 Reimbursement and Market Access
 
17 Appendix
 
17.1. Bibliography
 
17.2. Report Methodology
 
20 DelveInsight Capabilities
 
21 Disclaimer
 
22 About DelveInsight

DelveInsight's "Nasal Polyposis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Nasal Polyposis, historical and forecasted epidemiology as well as the Nasal Polyposis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Nasal Polyposis Market 

Nasal Polyposis Market Insight, Epidemiology And Market Forecast - 2034

DelveInsight's Nasal Polyposis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Nasal Polyposis..